EBRO 2017

Quartz trial

• Non-inferiority Phase 3 RCT • NSCLC brain mets • Primary outcome QUALYs (survival and EQ-5D) • Non-inferior if no less than 7 QUALY days • BSC + steroids vs BSC + steroids + RT (20Gy/5#) • 538 pts 72 centres